TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03017443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrisystem Turbo 10
Description: Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrisystem My Way
Description: The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (\~50% kcal from carbohydrate, \~25% from protein, \~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrisystem DASH
Description: The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included \< 30% fat (\< 7% saturated fat), \< 150 mg/d of cholesterol, and \< 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu \[7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week\], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dieting on Your Own (DIY) - DASH
Description: The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
Study: NCT04613050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Training
Description: Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
Study: NCT02766322

Intervention type: OTHER
Intervention: Intravenous Alcohol Self-administration Test
Description: Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit.
Study: NCT02766322

Intervention type: OTHER
Intervention: Intravenous Alcohol Self-administration Test
Description: Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit.

Intervention type: OTHER
Intervention: Intravenous Alcohol Self-administration Test
Description: Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit.

Intervention type: OTHER
Intervention: Intravenous Alcohol Self-administration Test
Description: Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit.

Intervention type: OTHER
Intervention: Intravenous Alcohol Self-administration Test
Description: Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit.
Study: NCT03051724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telematic follow up
Description: Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
Study: NCT01148563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-health Monitoring
Description: Daily tele-health monitoring data will be collected from randomized participants.
Study: NCT05685888

Intervention type: OTHER
Intervention: Medication history
Description: The study was retrospective and did not involve the application of interventions

Intervention type: OTHER
Intervention: Medication history
Description: The study was retrospective and did not involve the application of interventions
Study: NCT02806466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscopy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fiberoptic bronchoscopy
Study: NCT00566449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one dose daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074
Description: 10 mg daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074
Description: 30 mg daily for 4 weeks
Study: NCT04285944

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mavig X-ray Protective Drapes
Description: Mavig X-ray Protective Drapes®
Study: NCT01403467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: CPAP 8 cmH2O
Study: NCT02505542

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection
Study: NCT02570282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SST-6007
Description: SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
Study: NCT03903822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream
Study: NCT05573529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
Study: NCT03903822

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle topical cream
Study: NCT05573529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular lens implantation
Description: intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular lens implantation
Description: intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
Study: NCT04663139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xla1
Description: Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xla1
Description: Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01706354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthetic
Description: Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anaesthetic
Description: Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
Study: NCT02232295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recognise [TM]
Description: Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Box
Description: A resource used for many pain and disability states of the hands and feet.
Study: NCT00059618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341 (Bortezomib)
Description: Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
Study: NCT01022346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5217790
Description: RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
Study: NCT03670069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00803543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
Study: NCT02197975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010 Dose 1
Description: PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Study: NCT00803543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: Two tablets once a day for 24 weeks
Study: NCT04267822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521 oral tablet
Description: Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Study: NCT03928119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: public education and network construction
Description: Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
Study: NCT01154179

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Hypocaloric feeding
Description: This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
Study: NCT03212846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
Study: NCT01199055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
Study: NCT02197975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010 Dose 2
Description: PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI. Administered as 2 inhalations
Study: NCT01199055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
Study: NCT04593251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CALY-002
Description: 1-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-hour intravenous infusion
Study: NCT00980473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Laser Iridoplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan/ Timolol/Azopt
Study: NCT03733119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO
Study: NCT00820547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
Study: NCT03733119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methionine-Restricted Diet
Description: Given PO
Study: NCT00820547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Neoadjuvant: 100 mg/m2 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
Study: NCT00467376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: 3 times a day before each meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: 3 times a day before each meal
Study: NCT03569982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine care
Description: Including acupuncture, relaxation/breathing, and manual/touch modalities
Study: NCT00244959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg orally daily for 12 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: treatment received after breast cancer surgery
Study: NCT03341923

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses for daily disposable wear
Study: NCT00467376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: once daily
Study: NCT01111643

Intervention type: DEVICE
Intervention: Echocardiogram
Description: An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
Study: NCT01313507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NewGam
Description: The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
Study: NCT01644643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime - Avibactam ( CAZ-AVI)
Description: Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
Study: NCT01060943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KOKEN
Description: atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atelocollagen Filler
Description: 1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.